Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - PowerPoint PPT Presentation

Loading...

PPT – Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 PowerPoint presentation | free to download - id: 800ae1-Yzc1Y



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021

Description:

Research Beam added a report on “Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 ” Enquiry about report: – PowerPoint PPT presentation

Number of Views:30

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021


1
Type 2 Diabetes Mellitus Therapeutics in
Asia-Pacific Markets to 2021 - Increasing Usage
of Newer Therapies and Expanding Treatment
Population to Encourage Robust Growth
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
TELEPHONE 1 (503) 894-6022E-MAIL
sales_at_researchbeam.com
Published on Oct 2014
2


Report Overview
  • Scope
  • The current T2DM in the Asia-Pacific (APAC)
    market contains novel products, including
    Jardiance - a SGLT-2 inhibitor Victoza - a GLP-1
    receptor agonist and Galvus - a DPP-4 inhibitor.
  • - What are the competitive advantages of the
    existing novel drugs?
  • With over 500 active pipeline molecules, most of
    the late-stage investigational drug candidates
    are being evaluated, featuring improved dosing
    regimens and administration routes, in comparison
    to currently marketed products and combination
    therapies.
  • - Which classes of novel drugs are most
    prominent within the pipeline?
  • - Is there strong potential for the pipeline to
    address unmet needs within the T2DM market?
  • Analysis of clinical trials, since 2006,
    identified that the failure rates of T2DM
    molecules were highest in Phase II, at 54, with
    the overall attrition rate for T2DM at 82.6.
  • - How do failure rates vary by product stage of
    development, molecule type, and mechanism of
    action?
  • - How do other factors, such as average trial
    duration and trial size influence the costs and
    risks associated with product development?
  • Read More At http//www.researchbeam.com/type-2-d
    iabetes-mellitus-therapeutics-in-asia-pacific-to-2
    021-increasing-usage-of-newer-therapies-and-expand
    ing-treatment-population-to-encourage-robust-growt
    h-market

3


Table of Content
1 Table of Contents 1 Table of Contents 4 1.1
List of Tables 6 1.2 List of Figures 7 2
Introduction 9 2.1 Disease Overview 9 2.2
Classification 9 3 Marketed Products 43 3.1
Overview 43 3.2 Biguanides 44 4 Pipeline 70 4.1
Overview 70 4.2 Pipeline Distribution by Stage of
Development, Molecule Type and Program Type 71 5
Market Forecast to 2021 99 5.1 Geographical
Markets 99 5.2 Asia-Pacific Markets 99 6
Strategic Consolidations 113 6.1 Licensing Deals
113 6.2 Co-development Deals 120 7 Appendix
129 7.1 All Pipeline Drugs by Phase of
Development 129 7.2 Market Forecasts to 2021 146
4


Report Overview
Reasons to buy   This report will enable you to
- - Understand the clinical context of T2DM by
considering symptoms, etiology, pathophysiology,
epidemiology, diagnosis, and treatment options. -
Identify the therapeutic strategies, products,
and companies that dominate the current marketed
products landscape and recognize gaps and areas
of unmet need. - Identify key pipeline trends in
molecule type, administration route, mechanism of
action, and novelty. - Consider market
opportunities and potential risks by examining
trends in T2DM clinical trial size, duration, and
failure rate by stage of development, molecule
type, and mechanism of action. - Recognize the
late-stage pipeline molecules that have
demonstrated strong therapeutic potential in T2DM
by examining clinical trial data and
multi-scenario product forecast projections. -
Compare treatment usage patterns, annual therapy
costs, and market growth projections for China,
India, Australia, and Japan. - Discover trends in
licensing and co-development deals concerning
T2DM products and identify the major strategic
consolidations that have shaped the commercial
landscape. Enquire At http//www.researchbeam.c
om/type-2-diabetes-mellitus-therapeutics-in-asia-p
acific-to-2021-increasing-usage-of-newer-therapies
-and-expanding-treatment-population-to-encourage-r
obust-growth-market/enquire-about-report
5



FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/type-2-diabetes-mellit
us-therapeutics-in-asia-pacific-to-2021-increasing
-usage-of-newer-therapies-and-expanding-treatment-
population-to-encourage-robust-growth-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE 1 (800) 910-6452 DIRECT 1 (503)
894-6022E-MAIL sales_at_researchbeam.com
About PowerShow.com